107.10
+7.85%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kodiak Sciences
From its filings with the US Securities and Exchange Commission
Kodiak Sciences is based in Palo Alto, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker KOD. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $230.0m. At that date it held total assets of $351.5m and shareholders' equity of $157.4m.
Since its founding in 2009, Kodiak Sciences Inc. (“Kodiak,” the “Company,” “we” or “our”) has developed a new technology platform, the Antibody Biopolymer Conjugate (“ABC”) platform, for retinal medicines. Our goal is to prevent and treat the major causes of blindness by developing and commercializing next-generation therapeutics to address multiple unmet needs on the spectrum of retinal diseases.
Kodiak has developed three late-stage clinical programs based on its internal discovery and development engine. The lead investigational medicine, tarcocimab tedromer (“Zenkuda” or “KSI-301” or “tarcocimab”), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Zenkuda has a mean ocular half-life in humans of 20 days, approximately three times longer than approved anti-vascular endothelial growth factor ("VEGF") therapies, and is designed to maintain effective drug levels in ocular tissues for longer. Zenkuda is being developed as a mainstay intravitreal biologic monotherapy that provides high immediacy, driven by the enhanced formulation, and high durability, driven by the ABC platform and our science of durability, with the ultimate objective of providing, once approved, a flexible 1-month through 6-month label for all patients with retinal vascular disease (treatment-naïve, treatment-experienced, mild patients and severe patients).
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Oct 2018
- Employees
- 124
- Website
- kodiak.com ↗
- Head office
- 1250 PAGE MILL RD, PALO ALTO, CA, 94304
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Victor PerlrothChairman of the Board, Chief Executive Officer, Co-Founder, since 2009$2.0m
- Mr. John BorgesonChief Financial Officer, Executive Vice President, Secretary$1.4m
- Mr. Robert ProfusekLead Independent Director$144,940
- Dr. Felix BakerIndependent Director$58,440
- Mr. Charles BancroftIndependent Director$135,940
- Dr. Bassil DahiyatIndependent Director$113,440
- Dr. Richard LevyIndependent Director$108,440
- Dr. Taiyin YangIndependent Director$113,440
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 37
- Environment
- 53
- Social
- 43
- Governance
- 17
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kodiak Sciences Inc has a strong foundation in the pharmaceutical industry, backed by a team of experienced professionals.
- The company boasts a robust pipeline of innovative drug candidates, positioning them for future growth and increased market share.
- Kodiak Sciences Inc has established strategic partnerships with leading pharmaceutical companies, enhancing their capabilities and resources.
Weaknesses
- One of Kodiak Sciences Inc's weaknesses is its reliance on a limited number of drug candidates, which presents a risk in case of failure or delay in clinical trials.
- The company's relative newness in the industry may result in a lack of brand recognition and market trust compared to more established competitors.
- Kodiak Sciences Inc currently has a small market share and limited market presence, which can hinder their ability to compete with larger pharmaceutical companies.
Opportunities
- The increasing demand for innovative pharmaceutical products presents a significant opportunity for Kodiak Sciences Inc to expand its market reach.
- Advancements in technology and regulatory support for research and development create favorable conditions for Kodiak Sciences Inc to develop new drugs.
- Emerging markets offer untapped potential for the company to establish a strong presence and capture additional market share.
Threats
- Intense competition within the pharmaceutical industry poses a threat to Kodiak Sciences Inc's market position and profitability.
- The regulatory landscape and potential changes in healthcare policies could impact the company's ability to bring drugs to market or affect profitability.
- Failure to effectively protect intellectual property may expose Kodiak Sciences Inc to the risk of competitors imitating or infringing on their innovations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.